{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:51:57Z","timestamp":1793047917953,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50 NS091856"],"award-info":[{"award-number":["P50 NS091856"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AG073100"],"award-info":[{"award-number":["R01 AG073100"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50 NS091856"],"award-info":[{"award-number":["P50 NS091856"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50 NS123067"],"award-info":[{"award-number":["P50 NS123067"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Parkinson disease (PD) is a heterogeneous syndrome. There is a need for biology-driven subtyping to inform specific therapeutic strategies. In a two-center study with de novo and established PD cohorts, we use vesicular acetylcholine transporter ligand [<jats:sup>18<\/jats:sup>F]FEOBV brain PET to assess cholinergic systems changes in early to moderate PD. Principal component analysis (PCA) is applied to data from 245 PD subjects to define cholinergic subgroups at baseline. Three PD subgroups are identified: hypercholinergic (regional upregulation; 29%), mixed (regional upregulation and regional deficits; 40.8%) and hypocholinergic (regional deficits only; 30.2%). Evidence of upregulation is observed in the subcortical-anterior cortical regions, whereas cholinergic downregulation is found in posterior cortical regions. Cholinergic upregulation and downregulation exhibit distinct associations with clinical symptoms. Longitudinal analysis (2-3 year interval) in 128 PD subjects reveals differential progressions by subgroup. This subtyping approach expands understanding of cholinergic progression in PD and may inform identification of new therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41467-025-60815-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:51:12Z","timestamp":1751370672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A multicenter longitudinal study of cholinergic subgroups in Parkinson disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-6414","authenticated-orcid":false,"given":"Nicolaas I.","family":"Bohnen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-3287","authenticated-orcid":false,"given":"Stiven","family":"Roytman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sygrid","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0836-445X","authenticated-orcid":false,"given":"Fotini","family":"Michalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4408-2605","authenticated-orcid":false,"given":"Austin","family":"Luker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. H.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Koeppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Albin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-2960","authenticated-orcid":false,"given":"Prabesh","family":"Kanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60815_CR1","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/mds.29637","volume":"38","author":"R Albin","year":"2023","unstructured":"Albin, R. & Grotewold, N. What is the Parkinson pandemic?. Mov. Disord. 38, 2141\u20132144 (2023).","journal-title":"Mov. Disord."},{"key":"60815_CR2","unstructured":"Albin, R. L, Parkinson Disease (Oxford University Press, New York, NY, 2022)CONTEMPORARY NEUROLOGY SERIES."},{"key":"60815_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa, E., Garrido, A., Scholz, S. W. & Poewe, W. Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol. 20, 385\u2013397 (2021).","journal-title":"Lancet Neurol."},{"key":"60815_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.29708","volume":"39","author":"C Marras","year":"2024","unstructured":"Marras, C. et al. Transitioning from subtyping to precision medicine in Parkinson\u2019s disease: A purpose-driven approach. Mov. Disord. 39, 462\u2013471 (2024).","journal-title":"Mov. Disord."},{"key":"60815_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni, T. et al. A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 23, 178\u2013190 (2024).","journal-title":"Lancet Neurol."},{"key":"60815_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(24)00222-9","volume":"23","author":"G Carli","year":"2024","unstructured":"Carli, G., Roytman, S. & Bohnen, N. I. Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol. 23, 661 (2024).","journal-title":"Lancet Neurol."},{"key":"60815_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1474-4422(24)00225-4","volume":"23","author":"JG Goldman","year":"2024","unstructured":"Goldman, J. G. et al. Concerns with the new biological research criteria for synucleinopathy. Lancet Neurol. 23, 660\u2013661 (2024).","journal-title":"Lancet Neurol."},{"key":"60815_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41582-021-00486-9","volume":"17","author":"D Berg","year":"2021","unstructured":"Berg, D. et al. Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat. Rev. Neurol. 17, 349\u2013361 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"60815_CR9","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1093\/brain\/awad192","volume":"146","author":"N Okkels","year":"2023","unstructured":"Okkels, N. et al. Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies. Brain 146, 3690\u20133704 (2023).","journal-title":"Brain"},{"key":"60815_CR10","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1093\/brain\/awae069","volume":"147","author":"N Okkels","year":"2024","unstructured":"Okkels, N. et al. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes. Brain 147, 2308\u20132324 (2024).","journal-title":"Brain"},{"key":"60815_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.irn.2018.07.027","volume":"141","author":"NI Bohnen","year":"2018","unstructured":"Bohnen, N. I., Kanel, P. & M\u00fcller, M. L. T. M. Molecular imaging of the cholinergic system in Parkinson\u2019s disease. Int. Rev. Neurobiol. 141, 211\u2013250 (2018).","journal-title":"Int. Rev. Neurobiol."},{"key":"60815_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"E De Pablo-Fern\u00e1ndez","year":"2019","unstructured":"De Pablo-Fern\u00e1ndez, E., Lees, A. J., Holton, J. L. & Warner, T. T. Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol. 76, 470\u2013479 (2019).","journal-title":"JAMA Neurol."},{"key":"60815_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-017-0738-x","volume":"17","author":"S-M Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad, S.-M. & Postuma, R. B. Subtypes of Parkinson\u2019s disease: What do they tell us about disease progression?. Curr. Neurol. Neurosci. Rep. 17, 34 (2017).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"60815_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol. 21, 381\u2013392 (2022).","journal-title":"Lancet Neurol."},{"key":"60815_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.nucmedbio.2009.02.007","volume":"36","author":"MR Kilbourn","year":"2009","unstructured":"Kilbourn, M. R. et al. Positron emission tomography imaging of (2R,3R)\u22125-[(18)F]fluoroethoxybenzovesamicol in rat and monkey brain: a radioligand for the vesicular acetylcholine transporter. Nucl. Med. Biol. 36, 489\u2013493 (2009).","journal-title":"Nucl. Med. Biol."},{"key":"60815_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2967\/jnumed.113.124792","volume":"55","author":"M Petrou","year":"2014","unstructured":"Petrou, M. et al. In vivo imaging of human cholinergic nerve terminals with (-)\u22125-(18)F-fluoroethoxybenzovesamicol: biodistribution, dosimetry, and tracer kinetic analyses. J. Nucl. Med. 55, 396\u2013404 (2014).","journal-title":"J. Nucl. Med."},{"key":"60815_CR17","doi-asserted-by":"publisher","first-page":"33S","DOI":"10.2967\/jnumed.121.263198","volume":"63","author":"S Tiepolt","year":"2022","unstructured":"Tiepolt, S. et al. PET imaging of cholinergic neurotransmission in neurodegenerative disorders. J. Nucl. Med. 63, 33S\u201344S (2022).","journal-title":"J. Nucl. Med."},{"key":"60815_CR18","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1002\/cne.24541","volume":"526","author":"RL Albin","year":"2018","unstructured":"Albin, R. L. et al. Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study. J. Comp. Neurol. 526, 2884\u20132897 (2018).","journal-title":"J. Comp. Neurol."},{"key":"60815_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/(SICI)1096-9861(19990906)411:4<693::AID-CNE13>3.0.CO;2-D","volume":"411","author":"ML Gilmor","year":"1999","unstructured":"Gilmor, M. L. et al. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer\u2019s disease. J. Comp. Neurol. 411, 693\u2013704 (1999).","journal-title":"J. Comp. Neurol."},{"key":"60815_CR20","doi-asserted-by":"publisher","first-page":"21929","DOI":"10.1016\/S0021-9258(17)31734-9","volume":"269","author":"JD Erickson","year":"1994","unstructured":"Erickson, J. D. et al. Functional identification of a vesicular acetylcholine transporter and its expression from a \u201ccholinergic\u201d gene locus. J. Biol. Chem. 269, 21929\u201321932 (1994).","journal-title":"J. Biol. Chem."},{"key":"60815_CR21","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1046\/j.1471-4159.1998.71062411.x","volume":"71","author":"ML Gilmor","year":"1998","unstructured":"Gilmor, M. L., Counts, S. E., Wiley, R. G. & Levey, A. I. Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal pathway lesions. J. Neurochem. 71, 2411\u20132420 (1998).","journal-title":"J. Neurochem."},{"key":"60815_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/mds.28913","volume":"37","author":"S van der Zee","year":"2022","unstructured":"van der Zee, S. et al. Altered cholinergic innervation in DE Novo Parkinson\u2019s disease with and without cognitive impairment. Mov. Disord. 37, 713\u2013723 (2022).","journal-title":"Mov. Disord."},{"key":"60815_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.parkreldis.2021.09.018","volume":"91","author":"C Legault-Denis","year":"2021","unstructured":"Legault-Denis, C. et al. Normal cognition in Parkinson\u2019s disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV. Parkinsonism Relat. Disord. 91, 162\u2013166 (2021).","journal-title":"Parkinsonism Relat. Disord."},{"key":"60815_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00401-015-1392-5","volume":"129","author":"AKL Liu","year":"2015","unstructured":"Liu, A. K. L., Chang, R. C.-C., Pearce, R. K. B. & Gentleman, S. M. Nucleus basalis of Meynert revisited: anatomy, history and differential involvement in Alzheimer\u2019s and Parkinson\u2019s disease. Acta Neuropathol. 129, 527\u2013540 (2015).","journal-title":"Acta Neuropathol."},{"key":"60815_CR25","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/brain\/121.12.2249","volume":"121","author":"NR Selden","year":"1998","unstructured":"Selden, N. R., Gitelman, D. R., Salamon-Murayama, N. & Parrish, T. B. M. M. Mesulam, Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain 121, 2249\u20132257 (1998).","journal-title":"Brain"},{"key":"60815_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/B978-0-12-819975-6.00008-X","volume":"179","author":"TW Schmitz","year":"2021","unstructured":"Schmitz, T. W. & Zaborszky, L. Spatial topography of the basal forebrain cholinergic projections: Organization and vulnerability to degeneration. Handb. Clin. Neurol. 179, 159\u2013173 (2021).","journal-title":"Handb. Clin. Neurol."},{"key":"60815_CR27","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1002\/cne.23415","volume":"521","author":"M-M Mesulam","year":"2013","unstructured":"Mesulam, M.-M. Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer\u2019s disease. J. Comp. Neurol. 521, 4124\u20134144 (2013).","journal-title":"J. Comp. Neurol."},{"key":"60815_CR28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209606","volume":"103","author":"A Nishida","year":"2024","unstructured":"Nishida, A. et al. Frontoparietal-striatal network and nucleus basalis modulation in patients with Parkinson disease and gait disturbance. Neurology 103, e209606 (2024).","journal-title":"Neurology"},{"key":"60815_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.tins.2009.06.003","volume":"32","author":"D Eidelberg","year":"2009","unstructured":"Eidelberg, D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 32, 548\u2013557 (2009).","journal-title":"Trends Neurosci."},{"key":"60815_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1212\/WNL.0000000000000130","volume":"82","author":"F Holtbernd","year":"2014","unstructured":"Holtbernd, F. et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology 82, 620\u2013627 (2014).","journal-title":"Neurology"},{"key":"60815_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.neuroimage.2006.09.003","volume":"34","author":"C Huang","year":"2007","unstructured":"Huang, C. et al. Metabolic brain networks associated with cognitive function in Parkinson\u2019s disease. Neuroimage 34, 714\u2013723 (2007).","journal-title":"Neuroimage"},{"key":"60815_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.jcbfm.9600358","volume":"27","author":"Y Ma","year":"2007","unstructured":"Ma, Y., Tang, C., Spetsieris, P. G., Dhawan, V. & Eidelberg, D. Abnormal metabolic network activity in Parkinson\u2019s disease: test-retest reproducibility. J. Cereb. Blood Flow. Metab. 27, 597\u2013605 (2007).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"60815_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2967\/jnumed.117.202242","volume":"59","author":"SK Meles","year":"2018","unstructured":"Meles, S. K. et al. REMPET Study Group, The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage Parkinson disease. J. Nucl. Med. 59, 1437\u20131444 (2018).","journal-title":"J. Nucl. Med."},{"key":"60815_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1089\/brain.2020.0937","volume":"13","author":"V Gupta","year":"2023","unstructured":"Gupta, V., Booth, S. & Ko, J. H. Hypermetabolic cerebellar connectome in Alzheimer\u2019s disease. Brain Connect 13, 356\u2013366 (2023).","journal-title":"Brain Connect"},{"key":"60815_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neurobiolaging.2019.03.022","volume":"83","author":"Y Stern","year":"2019","unstructured":"Stern, Y., Barnes, C. A., Grady, C., Jones, R. N. & Raz, N. Brain reserve, cognitive reserve, compensation, and maintenance: operationalization, validity, and mechanisms of cognitive resilience. Neurobiol. Aging 83, 124\u2013129 (2019).","journal-title":"Neurobiol. Aging"},{"key":"60815_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3233\/JPD-202481","volume":"11","author":"P Borghammer","year":"2021","unstructured":"Borghammer, P. The \u03b1-Synuclein Origin and Connectome model (SOC model) of Parkinson\u2019s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J. Parkinsons. Dis. 11, 455\u2013474 (2021).","journal-title":"J. Parkinsons. Dis."},{"key":"60815_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ana.410370219","volume":"37","author":"P Anglade","year":"1995","unstructured":"Anglade, P., Tsuji, S., Javoy-Agid, F., Agid, Y. & Hirsch, E. C. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson\u2019s disease. Ann. Neurol. 37, 265\u2013272 (1995).","journal-title":"Ann. Neurol."},{"key":"60815_CR38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuroimage.2018.01.021","volume":"190","author":"K Kim","year":"2019","unstructured":"Kim, K., Bohnen, N. I., M\u00fcller, M. L. T. M. & Lustig, C. Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson\u2019s disease. Neuroimage 190, 94\u2013106 (2019).","journal-title":"Neuroimage"},{"key":"60815_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1037\/bne0000048","volume":"129","author":"A Kucinski","year":"2015","unstructured":"Kucinski, A. & Sarter, M. Modeling Parkinson\u2019s disease falls associated with brainstem cholinergic systems decline. Behav. Neurosci. 129, 96\u2013104 (2015).","journal-title":"Behav. Neurosci."},{"key":"60815_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.10069","volume":"51","author":"ST DeKosky","year":"2002","unstructured":"DeKosky, S. T. et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol. 51, 145\u2013155 (2002).","journal-title":"Ann. Neurol."},{"key":"60815_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11682-024-00872-z","volume":"18","author":"C Legault-Denis","year":"2024","unstructured":"Legault-Denis, C. et al. Parkinson\u2019s disease CA2-CA3 hippocampal atrophy is accompanied by increased cholinergic innervation in patients with normal cognition but not in patients with mild cognitive impairment. Brain Imaging Behav. 18, 783\u2013793 (2024).","journal-title":"Brain Imaging Behav."},{"key":"60815_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(18)30032-2","volume":"17","author":"S-Y Liu","year":"2018","unstructured":"Liu, S.-Y. et al. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson\u2019s disease: a cross-sectional PET study. Lancet Neurol. 17, 309\u2013316 (2018).","journal-title":"Lancet Neurol."},{"key":"60815_CR43","doi-asserted-by":"publisher","first-page":"fcac320","DOI":"10.1093\/braincomms\/fcac320","volume":"4","author":"NI Bohnen","year":"2022","unstructured":"Bohnen, N. I. et al. Progression of regional cortical cholinergic denervation in Parkinson\u2019s disease. Brain Commun. 4, fcac320 (2022).","journal-title":"Brain Commun."},{"key":"60815_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.nbd.2007.09.004","volume":"29","author":"RY Moore","year":"2008","unstructured":"Moore, R. Y., Whone, A. L. & Brooks, D. J. Extrastriatal monoamine neuron function in Parkinson\u2019s disease: an 18F-dopa PET study. Neurobiol. Dis. 29, 381\u2013390 (2008).","journal-title":"Neurobiol. Dis."},{"key":"60815_CR45","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"60815_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mds.21198","volume":"22","author":"CG Goetz","year":"2007","unstructured":"Goetz, C. G. et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov. Disord. 22, 41\u201347 (2007).","journal-title":"Mov. Disord."},{"key":"60815_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53, 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"key":"60815_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbas.2022.100039","volume":"2","author":"P Kanel","year":"2022","unstructured":"Kanel, P. et al. Cerebral topography of vesicular cholinergic transporter changes in neurologically intact adults: A [18F]FEOBV PET study. Aging Brain 2, 100039 (2022).","journal-title":"Aging Brain"},{"key":"60815_CR49","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1021\/acs.molpharmaceut.1c00961","volume":"19","author":"RL Albin","year":"2022","unstructured":"Albin, R. L. et al. No dopamine agonist modulation of brain [18F]FEOBV binding in Parkinson\u2019s disease. Mol. Pharm. 19, 1176\u20131182 (2022).","journal-title":"Mol. Pharm."},{"key":"60815_CR50","doi-asserted-by":"publisher","first-page":"fcab109","DOI":"10.1093\/braincomms\/fcab109","volume":"3","author":"NI Bohnen","year":"2021","unstructured":"Bohnen, N. I. et al. Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson\u2019s disease. Brain Commun. 3, fcab109 (2021).","journal-title":"Brain Commun."},{"key":"60815_CR51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/ana.25430","volume":"85","author":"NI Bohnen","year":"2019","unstructured":"Bohnen, N. I. et al. Cholinergic system changes of falls and freezing of gait in Parkinson\u2019s disease. Ann. Neurol. 85, 538\u2013549 (2019).","journal-title":"Ann. Neurol."},{"key":"60815_CR52","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/brain\/awad323","volume":"147","author":"S Slingerland","year":"2024","unstructured":"Slingerland, S. et al. Cholinergic innervation topography in GBA-associated de novo Parkinson\u2019s disease patients. Brain 147, 900\u2013910 (2024).","journal-title":"Brain"},{"key":"60815_CR53","doi-asserted-by":"publisher","first-page":"1006567","DOI":"10.3389\/fnagi.2022.1006567","volume":"14","author":"S van der Zee","year":"2022","unstructured":"van der Zee, S., Kanel, P., M\u00fcller, M. L. T. M., van Laar, T. & Bohnen, N. I. Identification of cholinergic centro-cingulate topography as main contributor to cognitive functioning in Parkinson\u2019s disease: Results from a data-driven approach. Front. Aging Neurosci. 14, 1006567 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"60815_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"60815_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01811-3","volume":"20","author":"JM Boertien","year":"2020","unstructured":"Boertien, J. M. et al. PPNN Study Group, Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson\u2019s disease patients for the identification and validation of biomarkers for Parkinson\u2019s disease subtypes, progression and pathophysiology. BMC Neurol. 20, 245 (2020).","journal-title":"BMC Neurol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60815-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60815-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:05:53Z","timestamp":1751371553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60815-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60815"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60815-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5655"}}